250 million people worldwide suffer from osteoporosis, a bone disease characterized by a decrease in bone mass and a deterioration of the bone microarchitecture resulting in an increased fracture risk.
The presence of prevalent fractures doubles the risk for sustaining another fractures within the next 12 months.
For those patients at very high, imminent fracture risk, bone specialists are lacking a fast-acting treatment without side-effects and negative impact on bone functions.
With flowbone, we address this treatment gap.
flowbone is a new generation of injectable biomaterial for a quick and subtle, local strengthening of fragile bones.
Unique mode of action
Once in place, flowbone initiates the apposition of the body's own minerals and rapidly turns into strong, viable bone
Compliance with bone biology
No foreign material, no interference with bone vascularization and biomechanics
flowbone is injected with a thin cannula into bone regions at hight risk of fracture
The technology behind flowbone has been developed at the Laboratory of Biomechanical Orthopedics at the Swiss Federal Institute of Technology Lausanne (EPFL). It was developed in collaboration with clinicians from the Lausanne University Hospital (CHUV).
All our products are still under development and not available on the market.
At flowbone, we aim for a world where the elderly can enjoy a high level of independence and quality of life, free from the devastating impact of fragility fractures.